Evaluate Pharma

Attending BIO‑Europe Spring and looking to sharpen your decision‑making? Evaluate’s Consulting team helps biopharma leaders find the right assets, prioritise partners, assess pipeline differentiation and spot emerging opportunities. Meet us at Booth 70. vist.ly/4vgny

We recently launched our annual Orphan Drugs Report, featuring forecasts for rare disease drugs through 2032. Read the full report on our website, or catch the quick summary on Fierce Pharma: vist.ly/4vepq. fiercepharma.com/pharma/rare-di…

TODAY: Melanie Senior and Andreas Hadjivasiliou dig into the rare disease shifts that are already changing how teams think about orphan drug strategy. Who is gaining ground, who is losing momentum, and how IRA pressure could reshape plans through 2032. vist.ly/4vemz

Tomorrow, Melanie Senior and Andreas Hadjivasiliou will break down how orphan drug sales, pipelines, and policy shifts like the IRA are shaping the rare disease market through 2032. Don’t miss Evaluate’s latest outlook. Watch live or on-demand. Register: vist.ly/4vagr

CNS is entering a new era fueled by scientific progress and rising urgency for better patient solutions. Hear Wen-Yu Huang on advances in neurodegeneration, psychiatry, rare CNS and clinical strategy. Mar 24, 11:15–12:00, Room Sintra. Booth 70. vist.ly/4vagm

Orphan drugs are at a crossroads… and the next chapter could be big. Here’s your 2‑minute primer before the webinar: vist.ly/4v6e6 Register for the webinar: vist.ly/4v6e4

If you work in orphan drugs, this webinar delivers the latest intelligence on sales, pipelines, policy shifts, and therapy area trends through 2032. Melanie Senior and Andreas Hadjivasiliou share where momentum is building and where it is fading. vist.ly/4v63t

Clients surveyed in 2025 called Evaluate a trusted, reliable, market‑leading source of pharmaceutical intelligence. They rely on us for accurate, timely insights that inform critical decisions. Evaluate is where commercial decisions start. Let’s talk: vist.ly/4v5zw

Organizations that need an accurate and clear view of the biopharma landscape start with Evaluate. Our consensus forecasts, connected insights, and transparent data help teams spot market potential and future risk. Learn more: vist.ly/4v3vb

Attending BIO‑Europe Spring and looking to sharpen your decision‑making? Evaluate’s Consulting team helps biopharma leaders find the right assets, prioritise partners, assess pipeline differentiation and spot emerging opportunities. Meet us at Booth 70. vist.ly/4uzuc

Many big pharma players are facing patent expiry in the next 5 years, and the pipeline is packed with competitive entrants. This forecasting report examines how the loss of exclusivity (LoE) and generic competition are influencing market planning. vist.ly/4uv2u.

vist.ly/4utva | Which companies and drugs topped the rankings in 2025? In his latest article for Nature, Paul Verdin uses Evaluate's data to examine the big hitters and the drivers of growth last year. (Subscription required). nature.com/articles/d4157…

Join BD&L Lead Ben Folwell as he covers partnerships, business models and data‑driven strategies advancing rare disease development, plus challenges in evidence, reimbursement and access. Mar 23, 16:30–17:15, Room Sintra. Booth 70. vist.ly/4uryf

Oncology is evolving fast. Join Ethan Smith, Director of Oncology, for insights on precision medicine, immunotherapy, novel modalities, development trends and market signals. Mar 23, 14:30–15:15, Room Sintra. Visit Evaluate at Booth 70. vist.ly/4umgv

Join Melanie Senior and Andreas Hadjivasiliou's webinar on understanding and competing in the orphan drug sales market. Learn how to stay competitive till 2026 & beyond. Register today to attend or get the recording: vist.ly/4uix2

When teams need clarity, they choose Evaluate. Our latest customer survey shows why leaders across pharma, consulting, and finance rely on us: trusted data, comprehensive insights, and an intuitive platform that drives confident decisions. vist.ly/4ud3k

Evaluate will be at the BIO-Europe Spring meeting partners, exploring collaborations, and showing how our data, insights and consulting expertise power smarter, faster strategic decisions. Visit us at Booth 70 and book time with our experts. 🔗 vist.ly/4u86z

vist.ly/4u66i | There are lots of sophisticated forecasting tools out there, so why do forecasters still use Excel? In this video blog, our forecasting guru, Andrew Ward, explains more about when and why Excel still has a place in the forecaster's toolkit. Watch now.

Efficiency pressures, shifting ownership, and rising audit expectations are reshaping forecasting fast. The function is becoming more centralised, accountable, and strategic. 👉 2026 Trends Report: vist.ly/4u3z4

Join Evaluate at BIO-Europe Spring as Daniel Chancellor, VP Thought Leadership at Norstella, breaks down emerging science, shifting pipelines, regulatory trends, and market forces shaping biopharma. vist.ly/4txji 📅 Mar 23 | 13:30–14:15 • Room Sintra • Booth 70